Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)

BACKGROUND: The activity of PD-1/PD-L1 inhibitors in the treatment of advanced bladder cancer (BC) is promising for many patients. However, a subset of patients do not benefit from treatment, thus leading to an effort to better identify predictive molecular biomarkers of response. OBJECTIVE: To cond...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Megan M., Ng, Terry L., De Jong, Florus C., Zuiverloon, Tahlita C.M., Fazzari, Francesco G.T., Theodorescu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747768/
https://www.ncbi.nlm.nih.gov/pubmed/33365377
http://dx.doi.org/10.3233/BLC-190218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747768/
https://www.ncbi.nlm.nih.gov/pubmed/33365377
http://dx.doi.org/10.3233/BLC-190218

Ejemplares similares